explore -WSS

explore

author：hotspot 2025-09-30 17:30:03 - browse：38461

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Overprescribed: High cost isn't America's only drug problem

leisure time

WSS

With competition flaring, obesity drug hits goal in liver disease study

A solution to the after

Overprescribed: High cost isn't America's only drug problem

Scientific mystery highlights the blind spots in genomics databases

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

knowledge

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Medical leaders decry Supreme Court decision on affirmative action

Medicare inequities exacerbate Puerto Rico’s health disparities

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

R1 RCM gets $5.8 billion buyout offer from private equity firm

Malaria cases in Florida and Texas: Here’s what you need to know

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Wildfire smoke exposes gaps in outdoor worker protections

The Harvard botanist who searched for psychedelics in the Amazon

explore

Insurer loopholes limit power of law against surprise medical bills

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Scientific mystery highlights the blind spots in genomics databases

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Medicare Advantage 2025 payments will dip, Biden administration says

NIH study of ME/CFS points to clear biological hallmarks

leisure time

entertainment

explore

focus